Search results
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Morningstar· 7 hours agoMedia Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI- ...
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse...
ABC 26 New Orleans· 5 hours agoPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced ...
Head to Head Survey: Replimune Group (NASDAQ:REPL) vs. CG Oncology (NASDAQ:CGON)
ETF DAILY NEWS· 2 weeks agoReplimune Group (NASDAQ:REPL – Get Free Report) and CG Oncology (NASDAQ:CGON – Get Free Report) are both medical companies, but which is the superior investment? We will compare ...